What has changed in the design and conduct of clinical trials between the pre- and post-Covid era? What role has technology played and will it continue to play? And how will the regulatory framework have to adapt to a new way of conducting trials, while respecting the utmost scientific rigour?

Elena Ottavianelli, Scientific Director of AICRO, spoke about this with Carlo Buonamico during the video interview published in Policy and Procurement in Healthcare: https://www.pphc.it/sperimentazioni-cliniche/